The ABCDs of moles and melanomas

Article

When you inspect moles, pay special attention to their sizes, shapes, edges, and color. A handy way to remember these features is to think of the A, B, C, and D of skin cancer-asymmetry, border, color, and diameter.

People at high risk of developing melanoma are those who have:

  • A family history of melanoma, or who have had a melanoma in the past

  • Unusual moles on the skin, or changing moles

  • Fair skin, light hair and eye color, and who sunburn easily or tan with difficulty

  • A record of painful or blistering sunburns as children or in their teenage years

  • Indoor occupations and outdoor recreational habits

When you inspect moles, pay special attention to their sizes, shapes, edges, and color. A handy way to remember these features is to think of the A, B, C, and D of skin cancer-asymmetry, border, color, and diameter.

Some forms of early malignant melanoma are asymmetrical, meaning that a line drawn through the middle will not create matching halves. Moles are round and symmetrical.
The borders of early melanomas are frequentlyuneven, often containing scalloped or notched edges. Common moles have smooth, even borders.
Different shades of brown or black are often the first sign of a malignant melanoma. Common moles usually have a single shade of brown.
Common moles are usualy less than 6 mm in diameter (1/4 in.), the size of a pencil eraser. Early melanomas tend to be larger than 6 mm.
Related Videos
Experts on myeloma
Related Content
Treatment with mRNA-4157 plus pembrolizumab yields benefits in resected melanoma subgroups in the phase 2 KEYNOTE-942 trial, including those with BRAF-mutated tumors.

mRNA Vaccine/Pembrolizumab Significantly Improves RFS in Resected Melanoma

October 23rd 2023
Article

Treatment with mRNA-4157 plus pembrolizumab yields benefits in resected melanoma subgroups in the phase 2 KEYNOTE-942 trial, including those with BRAF-mutated tumors.

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

OncView™ Podcast: Immunotherapy Response Monitoring in Melanoma

April 8th 2022
Podcast

John Kirkwood, MD, PhD, discussed considerations for treating patients with melanoma using immunotherapy and how to properly monitor responses.

Second-line end points of the TRICOTEL trial assessing atezolizumab plus vemurafenib and cobimetinib in melanoma with central nervous system metastases appear consistent with primary efficacy end points.

Atezolizumab Combo Results in Intracranial Activity in BRAFV600+ Melanoma

September 7th 2023
Article

Second-line end points of the TRICOTEL trial assessing atezolizumab plus vemurafenib and cobimetinib in melanoma with central nervous system metastases appear consistent with primary efficacy end points.

On this episode of CancerNetwork’s podcast, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY.

Oncology Peer Review On-The-Go: Patient Case of Metastatic Basal Cell Carcinoma Arising From a Carcinosarcoma

February 14th 2022
Podcast

On this episode of the Oncology® Peer Review On-The-Go, Emily Smith, MD, discussed a patient case of basal cell carcinoma she and colleagues published in the journal ONCOLOGY®.

Supporting data for the FDA approval of melphalan administered via percutaneous hepatic perfusion for metastatic uveal melanoma come from the phase 3 FOCUS study.

FDA Approves Melphalan Injection in Hepatic-Dominant Uveal Melanoma

August 15th 2023
Article

Supporting data for the FDA approval of melphalan administered via percutaneous hepatic perfusion for metastatic uveal melanoma come from the phase 3 FOCUS study.

Using the 31-gene expression profile assay may help lead to more personalized treatment strategies in patients with cutaneous melanoma, according to Aaron Farberg, MD.

31-GEP Assay May Help to Extend Survival in Cutaneous Melanoma

August 7th 2023
Article

Using the 31-gene expression profile assay may help lead to more personalized treatment strategies in patients with cutaneous melanoma, according to Aaron Farberg, MD.